News from vivus, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Mar 31, 2011, 06:45 ET

Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting

VIVUS, Inc. (Nasdaq: VVUS) today announced that data on QNEXA®, its investigational drug candidate, will be featured in a poster presentation...

Mar 29, 2011, 06:45 ET

VIVUS to Present at the 10th Annual Needham Healthcare Conference

VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the 10th Annual...

Feb 28, 2011, 16:00 ET

VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results

VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today...

Feb 25, 2011, 06:45 ET

VIVUS to Present at Three Upcoming Investor Conferences in March

VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at three...

Jan 21, 2011, 06:59 ET

VIVUS Provides Regulatory Update on QNEXA NDA

VIVUS, Inc. (Nasdaq: VVUS) today announced that it held an End-of-Review meeting with the Food and Drug Administration (FDA) for the New Drug...

Jan 05, 2011, 07:00 ET

VIVUS to Present at the 2011 JP Morgan Healthcare Conference

VIVUS, Inc. (Nasdaq: VVUS) today announced that Leland Wilson, chief executive officer, will present an overview of the company at the 29th Annual...

Dec 20, 2010, 06:45 ET

VIVUS Files European Marketing Authorization Application for QNEXA® in the Treatment of Obesity

VIVUS, Inc. (Nasdaq: VVUS) today announced that the company filed a Marketing Authorization Application (MAA) with the European Medicines Agency...

Dec 14, 2010, 06:45 ET

VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®

VIVUS, Inc. (Nasdaq: VVUS) today announced that the company, as part of its continuing effort to secure regulatory approval for QNEXA® in the...

Dec 06, 2010, 07:00 ET

VIVUS Announces Positive Results From Long-Term Phase 3 Study of Avanafil in Erectile Dysfunction

VIVUS, Inc. (Nasdaq: VVUS) today announced positive results from TA-314, a phase 3 pivotal open-label safety study of avanafil, an investigational...

Dec 03, 2010, 07:00 ET

VIVUS to Present at Two Upcoming Investor Conferences

VIVUS, Inc. (Nasdaq: VVUS) today announced that senior management will present an overview of the company at two investment conferences during the...

Nov 15, 2010, 16:15 ET

Data on VIVUS' QNEXA to be Presented at the American Heart Association Scientific Sessions 2010

VIVUS, Inc. (Nasdaq: VVUS) today announced that data on QNEXA®, an investigational drug candidate, will be featured in a poster presentation...

Nov 08, 2010, 16:00 ET

VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results

VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today...

Nov 08, 2010, 06:30 ET

VIVUS Announces Closing of MUSE Sale

VIVUS, Inc. (Nasdaq: VVUS) today announced that it has closed the sale of its MUSE business to Meda.  Under the purchase agreement, Meda...

Nov 04, 2010, 07:15 ET

VIVUS to Present at Two Upcoming Investor Conferences

VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at two...

Oct 28, 2010, 20:33 ET

FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®

VIVUS, Inc. (Nasdaq: VVUS) announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA)...

Oct 21, 2010, 06:45 ET

Data on VIVUS' QNEXA to Be Featured in Two Presentations at the First International Diabetes and Obesity Forum

VIVUS, Inc. (Nasdaq: VVUS) today announced that data on QNEXA®, an investigational drug candidate, will be featured in two oral presentations...

Oct 07, 2010, 06:45 ET

Data on VIVUS' QNEXA to be Presented in Six Posters at The Obesity Society's Annual Meeting

VIVUS, Inc. (Nasdaq: VVUS) today announced that data on QNEXA®, an investigational drug candidate, are highlighted in six poster presentations...

Oct 04, 2010, 09:55 ET

VIVUS Announces Sale of MUSE Assets to Meda

VIVUS, Inc. (Nasdaq: VVUS) today announced that it has entered into an asset purchase agreement with Meda - an international specialty pharma...

Sep 21, 2010, 16:18 ET

VIVUS Announces QNEXA Presentations at the European Association for the Study of Diabetes (EASD) Annual Meeting

VIVUS, Inc. (Nasdaq: VVUS) today announced that data on QNEXA(R), an investigational drug candidate, are featured in two poster presentations at...

Sep 21, 2010, 06:45 ET
Average weight loss over two years of therapy with QNEXA.  (PRNewsFoto/VIVUS, Inc.)

New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years

VIVUS, Inc. (Nasdaq: VVUS) today announced positive top-line results from a two-year study of QNEXA® (phentermine/topiramate) Controlled...